Neovacs gets payment for AllergyVacs, from National Agency for Research

Neovacs has received a first payment of a total amount up to €702.000, for its preclinical development program AllergyVacs, within the grant awarded by the National Agency for Research (ANR), conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute.

Neovacs’ proof of concept in allergies with its new IL-4 / IL-13 Kinoid therapeutic vaccine was recently presented at two major scientific congresses (Antibodies and Complement 2019 & EAACI 2019), with a strong interest manifested by the scientific and medical community, it said in the press release.

According to Neovacs, the study showed in a representative allergic asthma model that a treatment with IL-4 / IL-13 Kinoid enhanced the production of polyclonal antibodies, which neutralize the two targeted cytokines IL-4 and IL-13, both being development factors for allergic asthma, thus avoiding the occurrance of symptoms.